Last reviewed · How we verify

Citrate 4% — Competitive Intelligence Brief

Citrate 4% (Citrate 4%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant (chelating agent). Area: Hematology / Nephrology.

marketed Anticoagulant (chelating agent) Ionized calcium (Ca2+) Hematology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Citrate 4% (Citrate 4%) — Centre Hospitalier Universitaire Dijon. Citrate 4% acts as an anticoagulant by chelating calcium ions, preventing blood clotting in extracorporeal circuits such as dialysis and apheresis systems.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Citrate 4% TARGET Citrate 4% Centre Hospitalier Universitaire Dijon marketed Anticoagulant (chelating agent) Ionized calcium (Ca2+)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant (chelating agent) class)

  1. Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Citrate 4% — Competitive Intelligence Brief. https://druglandscape.com/ci/citrate-4. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: